from Arix Bioscience PLC (isin : GB00BD045071)
Unaudited NAV for September 2023
Arix Bioscience PLC (ARIX)
Arix Bioscience plc
Unaudited NAV for September 2023
LONDON, 6 October 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited estimated Net Asset Value (“NAV”) of the Company for the date ended 30 September 2023 as follows:
[ENDS]
Enquiries For more information on Arix, please contact:
Arix Bioscience plc +44 (0)20 7290 1050
Powerscourt Group Sarah MacLeod, Ibrahim Khalil, Nick Johnson +44 (0)20 7250 1446
About Arix Bioscience plc Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. | ||||||||||||||||||
| ISIN: | GB00BD045071 |
| Category Code: | NAV |
| TIDM: | ARIX |
| LEI Code: | 213800OVT3AHQCXNIX43 |
| OAM Categories: | 3.1. Additional regulated information required to be disclosed under the laws of a Member State |
| Sequence No.: | 276250 |
| EQS News ID: | 1742793 |
| End of Announcement | EQS News Service |